In 2025, the European Medicines Agency concluded that NAION should be listed as a very rare side effect of semaglutide medications, including Ozempic, Wegovy, and Rybelsus, after reviewing clinical studies, adverse event reports, and post-market safety data
While research is ongoing to determine if there is a direct causal link, most experts believe the connection is secondary
Despite challenges in terms of efficacy, selectivity, and safety, several classes of novel synthetic DNL inhibitors are currently in the clinical stage of development and may form the basis of a novel class of therapies (142)
Start with a physician consult labs, goals, and whether GLP-1 is even the right tool for you